Coronavirus Live Count Map India
remove_red_eye 588 Views
Coronavirus Live Count Map World
#Pathology and Lab Medicine #Pharmacist #Public Health #Pulmonary Medicine
Coronavirus FAQ PDF
The U.S. Food and Drug Administration has approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation.
Trikafta is approved for patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis population… (FDA, October 21, 2019)